| Author (Corporate) | European Commission |
|---|---|
| Series Title | COM |
| Series Details | (2013) 498 final (10.7.13) |
| Publication Date | 10/07/2013 |
| Content Type | Policy-making |
|
The European and Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 in response to the global health crisis caused by the three main poverty-related diseases — HIV/AIDS, malaria and tuberculosis — and to the EU’s commitment to achieving the United Nation’s Millennium Development Goals by 2015. The first EDCTP programme (EDCTP1, 2003-2012) is now beyond its active funding period. Despite the results and impact of EDCTP so far, the health and socio-economic burden of poverty-related diseases persists and hinders the sustainable development of developing countries, in particular in sub-Saharan Africa. More than one billion people, including 400 million children, are suffering from one or more poverty-related diseases, including neglected infectious diseases such as sleeping sickness and worm infections. HIV/AIDS alone kills an estimated 2 million people, while malaria and tuberculosis together kill an estimated 2.2 million people annually. In addition to creating unnecessary suffering and premature deaths these diseases undermine productivity and increase insecurity and infirmity, thus perpetuating the cycle of poverty. Sub-Saharan Africa is disproportionately affected by such diseases, with approximately 90% of all malaria-related deaths occurring in Africa. This region also accounts for over two thirds of all people living with HIV and for nearly three quarters of AIDS-related deaths. While general improvements in nutrition, sanitation and health infrastructure are important, the effective long-term control of poverty-related diseases also requires the development of new or improved medical interventions (products, treatments and vaccines). While there is a general lack of such medical products, many of the existing drugs and vaccines currently used date back to the early 20th century and, moreover, are no longer effective due to the emergence of drug resistance in these diseases. Most of the new drugs and vaccines under development, however, are stuck at the stage of early clinical development. This is mainly due to the significant costs involved in the clinical development and testing needed in humans to prove the effectiveness and safety of new or improved medical interventions. These costs are linked to three key problem drivers: (i) insufficient investment by the private sector due to a lack of return on investment (market failures), (ii) weak clinical research capacity in sub-Saharan African countries, and (iii) fragmented public support. Following the recommendations from the independent interim evaluation of EDCTP1 and the conclusions from the Member States’ meeting in September 2010, the Belgian EU Council Presidency proposed to the Competitiveness Council on 26 November 2010 the launch of a second EDCTP joint programme (EDCTP2) with at least ten years duration. To that end, the EDCTP1 participating states published a Strategic Business Plan 2014-2024 for EDCTP2. On these grounds, the Commission puts forward a proposal for a Decision on the participation of the EU in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) based on Article 185 of the Treaty on the Functioning of the EU, which makes provision for the EU to participate in research and development programmes undertaken by several Member States. |
|
| Source Link | Link to Main Source http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=COM:2013:498:FIN |
| Related Links |
|
| Subject Categories | Culture, Education and Research |
| Countries / Regions | Europe |
